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Abstract
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The retroviral restriction factors, TRIM5α and TRIMCyp, consist of RING and B-box 2 domains
separated by a coiled coil from carboxy-terminal domains. These carboxy-terminal domains (the
B30.2(SPRY) domain in TRIM5α and the cyclophilin A domain in TRIMCyp) recognize the
retroviral capsid. Here we show that some B-box 2 changes in TRIM5α, but not in TRIMCyp, resulted
in decreased human immunodeficiency virus (HIV-1) capsid binding. The phenotypic effects of these
B-box 2 changes on the restriction of retroviral infection depended on the potency of restriction and
the affinity of the TRIM5α interaction with the viral capsid, two properties specified by the B30.2
(SPRY) domain. Thus, some alterations in the TRIM5α B-box 2 domain apparently affect the
orientation or conformation of the B30.2(SPRY) domain, influencing capsid recognition.
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Introduction
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Retroviruses encounter potent blocks to infection in certain mammalian species. In many cases,
the restriction is mediated by dominant host factors, such as Fv1 (Best et al., 1996; Hartley,
Rowe, and Huebner, 1970; Lilly, 1967; Lilly, 1970), APOBEC3G (Sheehy et al., 2002) and
TRIM5α (Stremlau et al., 2004). TRIM5α blocks retroviral infection at an early post-entry step
in a species-specific manner. Rhesus monkey TRIM5α (TRIM5αrh) potently blocks the
infection of human immunodeficiency virus-1 (HIV-1) and a range of other retroviruses; by
contrast, human TRIM5α (TRIM5αhu) modestly restricts HIV-1 infection and potently blocks
infection by N-tropic murine leukemia viruses (N-MLV) (Hatziioannou et al., 2004;
Keckesova, Ylinen, and Towers, 2004; Perron et al., 2004; Stremlau et al., 2004; Yap et al.,
2004). The mechanism by which TRIM5α blocks retroviral infection has not been clearly
defined. Previous studies demonstrated that TRIM5α proteins specifically recognize the viral
cores and accelerate the uncoating process (Li et al., 2006c; Perron et al., 2006; Sebastian and
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Luban, 2005; Stremlau et al., 2006), thus potentially interfering with the orderly disassembly
of the viral capsid (Forshey et al., 2002).
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TRIM5α is a member of the large tripartite motif (TRIM) protein family (Reymond et al.,
2001). TRIM proteins contain RING, B-box 2 and coiled-coil domains; many cytoplasmic
TRIM proteins, like TRIM5α, also contain a B30.2(SPRY) domain (Meroni and Diez-Roux,
2005; Reymond et al., 2001). The B30.2(SPRY) domain of TRIM5α determines viral
specificity and potency of restriction by modulating recognition of the retroviral capsid
(Stremlau et al., 2005; Yap, Nisole, and Stoye, 2005; Perez-Caballero et al., 2005a; Li et al.,
2006c). For example, in an in vitro binding assay, the B30.2(SPRY) domain was shown to be
the major determinant of the association of TRIM5αrh with the assembled HIV-1 capsidnucleocapsid (CA-NC) complex (Li et al., 2006c; Stremlau et al., 2006).
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The role of TRIM5α domains other than the B30.2(SPRY) domain in antiretroviral activity
has been investigated. The RING finger domain is the signature of a class of E3 ubiquitin
ligases involved in proteasome-mediated protein degradation (Meroni and Diez-Roux, 2005).
Indeed, some TRIM proteins have been shown to exhibit ubiquitin ligase activity and modify
their target proteins with ubiquitin (Dupont et al., 2005; Horn et al., 2004; Meroni and DiezRoux, 2005; Trockenbacher et al., 2001; Xu et al., 2003). However, deletion of the TRIM5α
RING domain only partially attenuated antiviral activity (Javanbakht et al., 2005; PerezCaballero et al., 2005a; Stremlau et al., 2004). Moreover, TRIM5α-mediated restriction activity
was not affected by modulation of E1 ubiquitin ligase activity in a temperature-dependent cell
line (Perez-Caballero et al., 2005b). Finally, proteasome inhibitors did not impair the restriction
activity of TRIM5α (Perez-Caballero et al., 2005b; Stremlau et al., 2006; Anderson et al.,
2006; Wu et al., 2006). Proteasome inhibitors can rescue viral reverse transcription from the
TRIM5α-mediated restriction, but the mechanistic basis for this phenomenon is unknown
(Anderson et al., 2006; Wu et al., 2006). The B-box 2 domain plays an important but poorly
understood role in the function of TRIM proteins (Meroni and Diez-Roux, 2005; Reymond et
al., 2001). Deletion of the B-box 2 domain of TRIM5α eliminated its antiretroviral activities
(Javanbakht et al., 2005; Perez-Caballero et al., 2005a). It has been suggested that the RING
and B-box 2 domains may specify an “effector” function, either by recruiting an additional cofactor or by participating in particular types of self-association (Diaz-Griffero et al., 2006b;
Perez-Caballero et al., 2005a; Stremlau et al., 2006). The coiled-coil domain is known to be
essential for both homomultimerization and heteromultimerization of many TRIM proteins
(Cao et al., 1997; Javanbakht et al., 2006; Mische et al., 2005; Perez-Caballero et al., 2005a;
Reymond et al., 2001). TRIM5α trimerization, which depends on the coiled coil and the L2
linker region connecting the coiled-coil and B30.2 domains, contributes greatly to the avidity
for the retroviral capsid and the restriction of viral infection (Javanbakht et al., 2006).
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In this study, we altered a combination of residues in the B-box 2 domain of wild-type human
and rhesus monkey TRIM5α, as well as chimeric and mutant TRIM5α proteins, and examined
the effects of these changes on antiretroviral activity against human immunodeficiency virus-1
(HIV-1), N-tropic Moloney leukemia virus (N-MLV) and simian immunodeficiency virus
(SIVmac). The results show that, depending on the restriction potency of the parental proteins,
a property determined by the B30.2(SPRY) domain, the same alterations of the B-box 2 domain
can confer different phenotypes on retrovirus restriction. Moreover, the B-box 2 alterations
used in this study dramatically affected the association of the TRIM5α proteins with in vitro
assembled HIV-1 CA-NC complexes, suggesting a functional interplay between the
TRIM5α B-box 2 and the B30.2(SPRY) domains.
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Results
Differential effects of TRIM5α B-box 2 changes on HIV-1 and N-MLV restriction

NIH-PA Author Manuscript
NIH-PA Author Manuscript

Despite 87% sequence identity, rhesus monkey TRIM5α (TRIM5αrh) and human TRIM5α
(TRIM5αhu) exhibit differences in the spectrum of restricted retroviruses due to divergence in
the B30.2 domains (Perez-Caballero et al., 2005a; Perron, Stremlau, and Sodroski, 2006;
Stremlau et al., 2005; Yap, Nisole, and Stoye, 2005). TRIM5αrh more potently restricts HIV-1
infection than TRIM5αhu, whereas TRIM5αhu more potently restricts the infection of N-MLV
(Hatziioannou et al., 2004; Keckesova, Ylinen, and Towers, 2004; Perron et al., 2004; Stremlau
et al., 2004; Yap et al., 2004). In a previous study, we generated two B-box 2 mutants of
TRIM5αrh, each with a few amino acid residues changed to that seen in a relatively distant
TRIM protein relative, TRIM21 (Li et al., 2006b). The TRIM21 B-box 2 domain, in contrast
to B-box 2 domains of close TRIM5 relatives like TRIM6 or TRIM34, does not effectively
substitute for that of TRIM5αrh (Li et al., 2006b). Mutant Cluster I-A exhibits the following
changes: Q109E, E110K, V114A, I115L and L118V; Mutant Cluster II-A exhibits the
following changes: E120A, R121Q, Q123R and E124K (Figure 1). The wild-type and mutant
TRIM5αrh proteins were expressed in HeLa cells (Figure 2A). Both B-box 2 mutants restricted
HIV-1 infection nearly as efficiently as the wild-type TRIM5αrh protein (Figure 2B). However,
no anti-N-MLV activity was detected for either of the mutants. In fact, N-MLV infected cells
expressing the Cluster I-A and Cluster II-A TRIM5αrh mutants more efficiently than cells
transduced with the control LPCX vector; these mutants may exert dominant-negative effects
on the TRIM5αhu protein endogenously expressed in the HeLa cells. Thus, the B-box 2 changes
confer different phenotypes with respect to the anti-HIV-1 and the anti-N-MLV activities of
rhesus monkey TRIM5α.
To investigate the phenotypes of the B-box 2 mutants in the context of more potent restriction
against N-MLV infection, the same changes were introduced into TRIM5αhu. Interestingly,
both TRIM5αhu mutants retained anti-N-MLV activity, but lost the weak restricting activity
against HIV-1 associated with wild-type TRIM5αhu (Figure 2B). These results demonstrate
that changes in the B-box 2 domain of TRIM5α can affect both HIV-1 and N-MLV restriction.
Apparently, if the parental TRIM5α is a potent restrictor of a specific virus, then the restriction
activity directed against that virus can better tolerate the changes introduced into the B-box 2
domain.
The phenotypic effects of the B-box 2 changes are determined by the B30.2(SPRY) domain
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The determinants of species-specific differences in the potency of TRIM5α-mediated
restriction to HIV-1 and N-MLV largely reside in the B30.2(SPRY) domain (Perez-Caballero
et al., 2005a; Perron, Stremlau, and Sodroski, 2006; Stremlau et al., 2005; Yap, Nisole, and
Stoye, 2005). The B30.2 domain from TRIM5αrh is sufficient to confer potent anti-HIV-1
activity on TRIM5αhu, whereas the B30.2 domain from TRIM5αhu further increases the antiN-MLV potency of TRIM5αrh (Perez-Caballero et al., 2005a; Perron, Stremlau, and Sodroski,
2006; Stremlau et al., 2005; Yap, Nisole, and Stoye, 2005). To examine whether the effects of
the B-box 2 changes on restriction are influenced by the B30.2(SPRY) domain, the B-box 2
changes were introduced into two previously established chimerae, TRIM5α R(H286-493) and
TRIM5α H(R286-493) (Stremlau et al., 2005). TRIM5α R(H286-493) is rhesus monkey
TRIM5α containing a human TRIM5α B30.2(SPRY) domain; TRIM5α H(R286-493) is human
TRIM5α with a rhesus monkey TRIM5α B30.2(SPRY) domain. The residue numbering
scheme is based on the human TRIM5α sequence (Stremlau et al., 2005). The TRIM5α R
(H286-493) and H(R286-493) proteins, with wild-type or mutant B-box 2 domains, were
expressed in HeLa cells (Figure 3A). As expected (Stremlau et al., 2005), HeLa cells
overexpressing TRIM5α R(H286-493) were more susceptible to HIV-1 infection than cells
expressing wild-type TRIM5αrh; however, compared to cells transduced with the empty vector
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control (LPCX), the TRIM5α R(H286-493)-expressing cells still exhibited a strong restriction
against HIV-1 infection (Figure 3B). TRIM5α R(H286-493) restricted N-MLV infection
slightly more potently than TRIM5αrh for the range of viral doses used. Introduction of the
Cluster I-A and Cluster II-A changes into the TRIM5α R(H286-493) protein resulted in
restriction phenotypes different from those seen in the TRIM5αrh background. The TRIM5α
R(H286-493)(I) and TRIM5α R(H286-493)(II) proteins did not detectably block HIV-1
infection, whereas both mutants were almost as potent as the parent TRIM5α R(H286-493)
protein in restricting N-MLV infection.
As previously reported (Stremlau et al., 2005), human TRIM5α gained potent restriction
activity against HIV-1 upon acquiring the B30.2(SPRY) domain from TRIM5αrh (see
TRIM5α H(R286-493) in Figure 2B); the N-MLV-blocking activity of this chimera was
slightly diminished compared to that of TRIM5αhu. When the Cluster I-A and Cluster II-A
changes were introduced into TRIM5α H(R286-493), restriction activity against N-MLV was
completely lost, whereas the anti-HIV-1 activities of these mutants were maintained (Figure
3B). These results demonstrate that, in the presence of a B30.2(SPRY) domain that specifies
a strong restriction against a certain target virus, the effects of the Cluster I-A and Cluster IIA B-box 2 alterations can be functionally tolerated. On the other hand, if the B30.2(SPRY)
domain confers relatively weak restricting ability to the TRIM5α protein, the two sets of Bbox 2 alterations completely eliminate detectable antiviral activity.
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Effects of B-box 2 alterations on the restriction activities of human TRIM5α R332P
A single amino acid change (R332P) in the B30.2(SPRY) domain of human TRIM5α is able
to confer potent restricting ability against both HIV-1 and SIVmac infection, even though strong
SIV-restricting activity is not a characteristic of either TRIM5αrh or TRIM5αhu (Li et al.,
2006c; Stremlau et al., 2005; Yap, Nisole, and Stoye, 2005). To examine how changes in the
B-box 2 domain affect the multiple restriction activities of TRIM5αhu R332P, the Cluster I-A
and Cluster II-A alterations were combined with the R332P change in human TRIM5α; the
antiviral activities of these TRIM5αhu variants were tested in HeLa cells overexpressing these
proteins (Figure 4A). The two sets of B-box 2 changes completely abolished the ability of the
proteins to block HIV-1 and SIVmac infection (Figure 4B). Interestingly, the Cluster II-A
changes also greatly attenuated the ability of TRIM5αhu R332P to restrict N-MLV infection,
whereas the TRIM5αhu R332P variant with the Cluster I-A changes efficiently blocked NMLV infection (Figure 4C). Thus, many but not all of the antiviral activities of TRIM5αhu
R332P are sensitive to the B-box changes studied here.
The B-box 2 alterations decrease the capsid-binding abilities of TRIM5α
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TRIM5α variants from Old World monkeys specifically associate with HIV-1 capsid
complexes; this interaction depends on the TRIM5α B30.2 domain (Stremlau et al., 2006).
Human and New World monkey TRIM5α proteins associate less efficiently with HIV-1 capsid
complexes, accounting for the lack of HIV-1 restriction in cells of these species (Stremlau et
al., 2006; Li et al., 2006c). Because the B-box 2 changes in this study affected TRIM5α
restriction activity in a potency-dependent manner determined by the B30.2 domain, the Bbox 2 changes might affect the capsid-binding abilities of TRIM5α. To test this hypothesis, a
previously established in vitro HIV-1 CA-NC binding assay was employed (Li et al., 2006c;
Stremlau et al., 2006). As expected (Li et al., 2006c; Stremlau et al., 2006), TRIM5αrh
associated with the in vitro assembled HIV-1 CA-NC complexes efficiently; TRIM5αhu only
weakly associated with the complexes (Figure 5). TRIM5α H(R286-493), which has a B30.2
domain from TRIM5αrh, associated with the HIV-1 capsid complexes as efficiently as the wildtype TRIM5αrh. Conversely, TRIM5α R(H286-493), with the B30.2 domain of TRIM5αhu,
bound the HIV-1 capsid complexes inefficiently. To our surprise, both sets of B-box 2
alterations dramatically reduced the binding capabilities of TRIM5αrh, TRIM5α H(R286-493)
Virology. Author manuscript; available in PMC 2008 September 30.
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and TRIM5αhu. The Cluster I-A and Cluster II-A changes did not cause any perceptible
reduction in the binding of TRIM5α R(H286-493) to HIV-1 CA-NC complexes, possibly due
to the low binding level seen for the unmodified TRIM5α R(H286-493) protein and the
sensitivity of this assay. These results indicate that the Cluster I-A and Cluster II-A changes
in the B-box 2 domain generally affect the capsid-binding affinity of TRIM5α proteins.
The B-box 2 alterations do not affect trimerization and subcellular localization of TRIM5α
On the linear sequence of TRIM5α the B-box 2 domain is separated from the B30.2 domain
by the coiled coil. One possible explanation for how changes in the B-box 2 domain could
affect capsid binding is that the B-box 2 domain may be required to correctly orient the coiledcoil domain for trimerization, which in turn increases the avidity of TRIM5α for retroviral
capsids (Javanbakht et al., 2006). To evaluate this possibility, TRIM5αrh and TRIM5α H
(R286-493) and their derived B-box 2 mutants were subjected to crosslinking with
glutaraldehyde. As shown in Figure 6, the Cluster I-A and Cluster II-A B-box 2 alterations do
not significantly affect the ability of TRIM5α proteins to trimerize.

NIH-PA Author Manuscript

Deletions or alterations of the TRIM5α RING and B-box 2 domains are in some cases
associated with changes in the subcellular localization of the mutant protein (Diaz-Griffero et
al., 2006a; Diaz-Griffero et al., 2006b; Javanbakht et al., 2005; Reymond et al., 2001).
However, neither of the B-box 2 alterations studied here caused redistribution of the
TRIM5α proteins (Figure 7). Within the limits of our ability to detect, the subcellular
localization of the Cluster I-A and Cluster II-A mutants exhibited cytoplasmic localizations
similar to those of the parental TRIM5α variants.
Phenotype of B-box 2 changes in owl monkey TRIMCyp
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A retrotransposition that occurred near the root of the owl monkey lineage of New World
monkeys resulted in a replacement of the TRIM5 gene with TRIMCyp (Nisole et al., 2004;
Ribeiro et al., 2005; Sayah et al., 2004). The encoded TRIMCyp protein consists of a fusion
of the RING, B-box 2 and coiled coil of TRIM5 with cyclophilin A. Because cyclophilin A
interacts with the capsid proteins of HIV-1 and at least a few other retroviruses (Franke, Yuan,
and Luban, 1994; Gamble et al., 1996; Lin and Emerman, 2006; Yoo et al., 1997), TRIMCyp
can restrict infection by these viruses (Diaz-Griffero et al., 2006b; Nisole et al., 2004; Sayah
et al., 2004; Zhang et al., 2006). Because cyclophilin A can bind with low affinity to monomeric
HIV-1 capsid proteins (Yoo et al., 1997), the interaction of TRIMCyp with retroviral capsids
may be less sensitive to B-box 2 changes than TRIM5α-capsid interaction. To test this
hypothesis, the abilities of wild-type TRIMCyp and B-box 2 Cluster I-A and Cluster II-A
mutants to bind HIV-1 CA-NC complexes were compared. Figure 8A shows that neither of
the B-box 2 alterations detectably affected the binding affinity of TRIMCyp for the assembled
HIV-1 capsid complexes.
The effect of the Cluster I-A and Cluster II-A changes in the TRIMCyp B-box 2 domain on
the ability to restrict HIV-1 infection was examined. The B-box 2 TRIMCyp mutants blocked
HIV-1 infection nearly as efficiently as wild-type TRIMCyp (Figure 8B). None of the
TRIMCyp variants inhibited N-MLV infection, as expected from the inability of cyclophilin
A to interact with MLV capsids (Braaten, Franke, and Luban, 1996). We conclude that the
Cluster I-A and Cluster II-A alterations do not appreciably affect TRIMCyp capsid interaction
or antiviral activity.
Phenotype of B-box 2 changes in the context of a TRIM5-Cyp chimera
The different phenotypes associated with the Cluster I-A and Cluster II-A B-box 2 changes in
the contexts of TRIM5α and TRIMCyp proteins could formally be attributed to the use of
cyclophilin A to bind the retroviral capsid or to the differences between the TRIM domains of
Virology. Author manuscript; available in PMC 2008 September 30.
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TRIM5α and TRIMCyp. To distinguish these possibilities, we created and tested rhRBCCCyp, in which the cyclophilin A domain from owl monkey TRIMCyp replaces the B30.2
(SPRY) domain of TRIM5αrh (Figure 1). The Cluster I-A and Cluster II-A B-box 2 changes
were introduced into the rhRBCC-Cyp protein. These B-box 2 changes did not affect the ability
of the rhRBCC-Cyp protein to bind HIV-1 CA-NC complexes (Figure 9A). The abilities of
the rhRBCC-Cyp Cluster I-A and Cluster II-A mutants to restrict HIV-1 infection were as great
as that of the unmodified rhRBCC-Cyp protein (Figure 9B). The rhRBCC-Cyp proteins did
not efficiently inhibit N-MLV infection (Figure 9C). We conclude that the Cluster I-A and
Cluster II-A B-box 2 changes do not affect capsid binding and HIV-1 restriction when the
capsid-binding moiety is cyclophilin A.

Discussion
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Changes in the B-box 2 domains of TRIM5α and TRIMCyp proteins have been shown to
diminish or abolish antiretroviral activity (Diaz-Griffero et al., 2006b; Javanbakht et al.,
2005; Li et al., 2006b; Perez-Caballero et al., 2005a). Some of these changes do not appreciably
decrease expression levels, alter subcellular localization or affect the capsid-binding ability of
the TRIM5α/TRIMCyp proteins (Diaz-Griffero et al., 2006b; Stremlau et al., 2006). These Bbox 2 changes apparently influence an “effector” function of TRIM5α/TRIMCyp that operates
after capsid binding. The nature of this effector function is not known; it may be involved in
the accelerated uncoating of the retroviral capsid that is strongly correlated with TRIM5α
restriction of viral infection (Perron et al., 2006; Stremlau et al., 2006).

NIH-PA Author Manuscript

Here we studied two clusters (Cluster I-A and Cluster II-A) of TRIM5α B-box 2 changes
involving residues that differ between TRIM5 and the distant relative TRIM21. The TRIM21
B-box 2 domain very inefficiently substitutes for that of TRIM5α, compared with the B-box
2 domains of the closer TRIM5 relatives, TRIM6 and TRIM34 (Li et al., 2006b). On models
of the B-box 2 domain based upon the TRIM29 B-box 2 structure, most of the residues involved
in the Cluster I-A and Cluster II-A changes are predicted to be surface-exposed (data not
shown). A key observation of our studies is that the viral restriction phenotypes of the Cluster
I-A and Cluster II-A B-box 2 mutants of TRIM5α are conditional, influenced by both the
TRIM5α background and the restricted virus. The phenotypes of the B-box 2 mutants are
generally correlated with the potency of the restriction against the particular viruses by the
TRIM5α parent with unmodified B-box 2 sequences. By analyzing recombinant TRIM5α
proteins, we show that the determinant of the conditional B-box 2 phenotype is the TRIM5α
B30.2(SPRY) domain, which makes major contributions to capsid binding (Stremlau et al.,
2006). Direct analysis of binding to HIV-1 capsid-nucleocapsid complexes revealed the
surprising finding that both Cluster I-A and Cluster II-A B-box changes caused substantial
reductions in capsid-binding affinity of TRIM5α proteins. These results indicate that the
decreases in TRIM5α antiretroviral function associated with the Cluster I-A and Cluster II-A
changes, by definition, do not result from disruption of an effector function. This conclusion
is consistent with the expectation that TRIM5α mutants with true effector function defects will
exhibit a restriction phenotype regardless of the high affinity of TRIM5α for the capsid, as has
been previously observed (Diaz-Griffero et al., 2006b; Stremlau et al., 2006).
We considered several possible explanations for the unexpected effect of the Cluster I-A and
Cluster II-A B-box 2 changes on TRIM5α binding to the retroviral capsid:
1.

Because TRIM5α trimerization contributes greatly to the avidity for assembled HIV-1
capsid complexes (Javanbakht et al., 2006) and because of the proximity of the Bbox 2 and coiled-coil domains, it is possible that the alterations introduced into the
B-box 2 domain affected TRIM5α trimer formation or stability. However, we
observed no differences in trimerization between the TRIM5α proteins with and
without Cluster I-A and Cluster II-A changes.

Virology. Author manuscript; available in PMC 2008 September 30.
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2.

The Cluster I-A and Cluster II-A changes could hypothetically disrupt B-box 2
contributions to capsid-binding affinity that are mediated by B-box 2-capsid contacts
or by B-box 2 interactions with cellular cofactors that promote higher avidity.
However, such models are incompatible with previous observations that the
TRIM5α B-box 2 domain can be disrupted or deleted with no apparent decrease in
capsid-binding affinity (Stremlau et al., 2006).

3.

The Cluster I-A and Cluster II-A B-box 2 changes might alter capsid-binding avidity
by influencing the orientation of the B30.2(SPRY) domains. The available data are
compatible with this explanation. In particular, our observations with TRIMCyp and
rh5RBCC-Cyp mutants indicate the specificity of the effects of these B-box 2 changes
for TRIM5 proteins with B30.2(SPRY) domains. The Cluster I-A and Cluster II-A
B-box 2 changes exerted no detectable effect on the ability of TRIMCyp or rh5RBCCCyp to bind HIV-1 capsid complexes. In the TRIMCyp and rh5RBCC-Cyp proteins,
the capsid-binding moiety of TRIM5α, the B30.2(SPRY) domain, is replaced by
cyclophilin A. Thus, the disruptive effects of the Cluster I-A and Cluster II-A B-box
2 changes on HIV-1 capsid binding are apparently dependent on the B30.2(SPRY)
domains being the direct capsid-binding entity; these disruptive effects are completely
eliminated when the capsid recognition function is mediated by the cyclophilin A
domain. These observations support a model in which the B-box 2 and B30.2 domains
are spatially related on TRIM5α proteins. Presumably the spatial relationships and
potential packing contacts involving the B-box 2 and B30.2(SPRY) domains on the
TRIM5α trimer differ from those of the B-box 2 and cyclophilin A domains on the
TRIMCyp trimer. Thus, in this model, the effects of Cluster I-A and Cluster II-A Bbox 2 changes on capsid binding are expected to differ for TRIM5α and TRIMCyp
proteins.

The observed effects of the Cluster I-A and Cluster II-A B-box 2 changes on capsid binding
could be mediated by direct B-box 2 - B30.2(SPRY) contacts or by indirect alteration of subunit
relationships on the trimer. Precise understanding of these relationships awaits a TRIM5α
structure.
We note that the binding of the Cluster I-A B-box 2 mutants to HIV-1 CA-NC complexes was
generally very low, and did not demonstrate an increase even for TRIM5α proteins
(TRIM5αrh (I) and TRIM5α H(R286-493) (I)) that exhibited HIV-1-restricting ability. These
observations suggest that, at least for TRIM5α proteins like the Cluster I-A mutants whose
level of expression is low, the HIV-1 capsid-binding assay is not sensitive enough to allow
precise assessment of affinities that, although low, can still influence biological phenotypes.
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Although replacement of the TRIM5αhu B30.2(SPRY) domain with the complete B30.2
(SPRY) domain of TRIM5αrh reverted the HIV-1-restriction phenotype of the Cluster I-A and
Cluster II-A B-box 2 changes, the replacement of arginine 332 in the B30.2(SPRY) domain
did not. This is consistent with previous observations suggesting that, although the presence
of arginine at residue 332 is the major determinant of the poor anti-HIV-1 potency of
TRIM5αhu, its replacement is not sufficient to achieve the same levels of HIV-1 capsid binding
and restriction as those of TRIM5αrh(Li et al., 2006c). Thus, TRIM5αhu R332P has apparently
gained sufficient affinity for the HIV-1 (and possibly SIVmac) capsids to allow restriction, but
not enough to counteract the influence of these particular B-box 2 alterations.
Further studies of TRIM5α and TRIMCyp may provide an understanding of the structural basis
of the functional inter-domain relationships elucidated in this work.
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Materials and Methods
Plasmid construction
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Mutations affecting the B-box 2 domain of the wild-type human and rhesus monkey
TRIM5α proteins were introduced into pLPCX-TRIM5α expression plasmids, using
overlapping PCR extension with primers carrying the corresponding nucleic acid changes
(Horton et al., 1993; Horton et al., 1989). The PCR-amplified TRIM5 fragments were digested
and cloned into the EcoRI and ClaI sites of the pLPCX vector, as previously described
(Stremlau et al., 2004). The chimeric constructs containing B-box 2 alterations were created
by exchanging fragments generated by BsmI and ClaI digestion of the above constructs and
similarly digested plasmids expressing TRIM5α R(H286-493), TRIM5α H(R286-493),
TRIM5αhu R332P or TRIMCyp (Stremlau et al., 2005). The rh5RBCC-Cyp protein contains
residues 1-296 of TRIM5αrh (MASGIL...FRELTDA296) fused to the Cyp A domain from owl
monkey TRIMCyp. The junction of the TRIM5αrh and TRIMCyp moieties in the rh5RBCCCyp has the following sequence: ...FRELTDAQRYWDAAAWDLVASAMVNPTV... All
constructs contain C-terminal epitope tags derived from influenza hemagglutinin (HA).
Creation of cells stably expressing TRIM proteins
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Recombinant viruses were produced in 293FT cells (Invitrogen) by cotransfecting the pLPCX
plasmids expressing TRIM proteins with the pVPack-GP and pVPack-VSV-G packaging
plasmids (Stratagene). The pVPack-VSV-G plasmid encodes the vesicular stomatitis virus
(VSV) G envelope glycoprotein, which allows efficient entry into a wide range of vertebrate
cells (Yee, Friedmann, and Burns, 1994). The resulting virus particles were used to transduce
2 × 105 HeLa cells in six-well plates. The transduced HeLa cells were then selected in 1 μg/
ml puromycin (Sigma).
Immunoblotting
HeLa cells stably expressing the transduced proteins were lysed with phosphate-buffered saline
(2.7 mM KCl, 1.5 mM KH2PO4, 138 mM NaCl, 8 mM Na2PO4) containing 1% NP40 and
protease inhibitor cocktail (Roche). The lysates were resolved by SDS-PAGE and Western
blotted with horseradish peroxidase (HRP)-conjugated anti-HA antibody (Roche) and anti-βactin antibody (Sigma).
Infection with viruses expressing GFP

NIH-PA Author Manuscript

Recombinant HIV-1, SIVmac, and N-MLV viruses expressing green fluorescent protein (GFP)
were made as previously described (Perron et al., 2004; Stremlau et al., 2004). For infection,
3 × 104 cells were seeded in 24-well plates and incubated with the viruses for 60 hours. Cells
were then washed with PBS, fixed with 3.7% formaldehyde and subjected to fluorescenceactivated cell sorting (FACS) analysis with a FACScan (Becton Dickinson).
Crosslinking of TRIM proteins
Cell lysates prepared in 1% NP40/PBS/protease inhibitor cocktail were incubated with varying
concentrations (final concentration: 0, 0.2, 0.4, 0.8 and 2.0 mM) of glutaraldehyde (Sigma) at
room temperature for 5 minutes, followed by adding excess glycine to quench the reaction.
The crosslinked lysates were then subjected to SDS-PAGE and Western blotted with HRPconjugated anti-HA antibody (Roche).
Subcellular localization using immunofluorescence confocal microscopy
HeLa cells stably expressing TRIM5α variants were cultured on 8-well chamber slides.
Twenty-four hours later, the cells were fixed, permeabilized, and incubated with rat anti-HA
3F10 antibody (1:200, Roche) followed by secondary anti-rat IgG conjugated with FITC
Virology. Author manuscript; available in PMC 2008 September 30.
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(1:200, Santa Cruz). The processed cells were analyzed using a confocal microscope (Nikon
Eclipse E800) with laser (Bio-Rad MRC 1024), and the images were obtained using Bio-Rad
Lasersharp 2000 software.
HIV-1 capsid-binding assay
Purification of recombinant HIV-1 CA-NC protein from Escherichia coli was carried out as
previously described (Ganser et al., 1999). For a source of TRIM5 proteins, HeLa cells stably
expressing the TRIM5 variants were lysed by freeze-thawing in hypotonic lysis buffer (10 mM
Tris, pH 7.4, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT) containing protease inhibitor (Roche).
The lysates were then mixed with the in vitro assembled HIV-1 CA-NC complexes and the
binding assay was carried out as previously described (Li et al., 2006a; Li et al., 2006c; Stremlau
et al., 2006).
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Figure 1. TRIM5 and TRIMCyp constructs
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The human and rhesus monkey TRIM5α proteins, TRIM5αhu and TRIM5αrh chimeric proteins,
and the owl monkey TRIMCyp protein are depicted. A chimeric rh5RBCC-Cyp protein in
which the amino-terminal portion of TRIM5αrh was fused with the cyclophilin A domain of
owl monkey TRIMCyp was also studied. The changes introduced into the B-box 2 domain of
the proteins to create the Cluster I-A and II-A mutants are shown. The carboxy-terminal HA
tag is shown.

NIH-PA Author Manuscript
Virology. Author manuscript; available in PMC 2008 September 30.

Li et al.

Page 13

NIH-PA Author Manuscript
NIH-PA Author Manuscript
Figure 2. Expression and antiretroviral activity of TRIM5αB-box 2 mutants
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(A).The expression level of TRIM5α proteins with C-terminal HA tags in HeLa cells stably
expressing these proteins was determined by Western blotting comparable amounts of cell
lysate with an anti-HA antibody. The blot was also probed for β-actin to control for loading
amount. Rh5, wild-type rhesus monkey TRIM5α; hu5, wild-type human TRIM5α; the mutants
labeled X(I) contain the Cluster I-A B-box 2 domain changes Q109E, E110K, V114A, I115L
and L118V; the mutants labeled X(II) contain the Cluster II-A B-box 2 domain changes E120A,
R121Q, Q123R and E124K, where X represents the TRIM5 backbone (X = rh5, rhesus monkey
TRIM5α; X = hu5, human TRIM5α) in which the changes were made. (B). The effects of the
TRIM5α proteins described above on retroviral infection were assessed. HeLa cells stably
expressing the wild-type and mutant TRIM proteins, or control HeLa cells transduced with the
empty LPCX vector, were incubated with various amounts of HIV-1-GFP or N-MLV-GFP.
Infected GFP-positive cells were counted by FACS. Twenty microliters of the preparation of
HIV-1-GFP used in these experiments correspond to ∼3,000 cpm reverse transcriptase units;
100 microliters of N-MLV-GFP correspond to ∼400 cpm reverse transcriptase units.
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Figure 3. Expression and antiretroviral activity of TRIM5αrh-TRIM5αhu chimerae with B-box 2
changes

(A). Expression of the unmodified (wt) TRIM5α R(H286-493) and H(R286-493) proteins and
the Cluster I-A (I) and Cluster II-A (II) mutants was examined by Western blotting lysates
from HeLa cells with an anti-HA antibody (Roche). Lysates were Western blotted for β-actin
as a control. Rh5 = wild-type TRIM5αrh. (B). Infection with HIV-1-GFP and N-MLV-GFP of
HeLa cell lines stably expressing the indicated parental and mutant proteins. The results shown
are typical of those obtained in two repeat experiments. (rh5 = TRIM5αrh; hu = TRIM5αhu).
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Figure 4. Effects of B-box 2 domain changes on the antiretroviral activity of human TRIM5α R332P

(A). Expression of the mutant proteins in HeLa cells was analyzed by Western blotting, as
described in the Figure 1 legend. Lysates were also blotted with an antibody against β-actin as
a control. (hu5 R332P = TRIM5αhu R332P). (B and C). HeLa cells expressing the indicated
proteins were incubated with HIV-1-GFP and SIVmac-GFP (B) and N-MLV-GFP (C), then
analyzed for GFP expression by FACS. Ten dose units of this preparation of SIVmac correspond
to ∼3000 cpm reverse transcriptase units. The experiment was repeated twice with results
similar to those shown.
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Figure 5. Effects of the B-box 2 changes on the association of TRIM5 proteins with assembled HIV-1
capsid complexes
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Cell lysates of HeLa cells stably expressing the C-terminally HA-tagged TRIM5 variants were
used in the HIV-1 CA-NC binding assay. The top and middle panels show the amounts of
TRIM5 protein in the input and pellet, respectively; the bottom panel shows the amount of
HIV-1 CA-NC protein that was pelleted through the 70% sucrose cushion. None of the TRIM5
protein variants were able to pellet through the 70% sucrose cushion in the absence of added
HIV-1 CA-NC complexes (data not shown). (hu5 = human TRIM5α; rh5 = TRIM5αrh; wt =
wild-type; I = Cluster I-A mutant; II = Cluster II-A mutant).
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Figure 6. Oligomerization of TRIM5α protein variants

Lysates from HeLa cells stably expressing the indicated TRIM5α proteins were crosslinked
with increasing concentrations of glutaraldehyde (0, 0.2, 0.4, 0.8 and 2.0 mM). The crosslinked
products were resolved by SDS-PAGE and visualized by Western blotting with an anti-HA
antibody. The position of the molecular weight markers is indicated on the figure.
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Figure 7. Localization of TRIM5α protein variants
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HeLa cells stably expressing the indicated HA-tagged TRIM5α proteins (or the empty LPCX
vector) were fixed and permeabilized. Cells were stained with an anti-HA antibody followed
by a secondary anti-rat IgG antibody conjugated with FITC. Stained cells were examined using
a confocal fluorescent microscope. The unmodified TRIM5α proteins (wt) are shown in the
left column, and the Cluster I-A and Cluster II-A variants of each protein in the middle and
right columns, respectively.
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Figure 8. Effects of B-box 2 changes on TRIMCyp function

(A). The indicated TRIM5α and TRIMCyp variants were expressed stably in HeLa cells. Cell
lysates were incubated with HIV-1 CA-NC complexes and the mixtures were layered onto a
70% sucrose cushion and centrifuged. The TRIM5α and TRIMCyp proteins in the input and
pellet were detected by Western blotting with an anti-HA antibody. The CA-NC protein in the
pellet was detected by Western blotting with an anti-p24 antibody. . (B and C). HeLa cells
stably expressing the indicated TRIM5α or TRIMCyp variants were exposed to the indicated
amounts of HIV-1-GFP (B) or N-MLV-GFP (C). GFP-positive cells were counted. The results
shown are those of a typical experiment; the experiment was repeated with similar results.
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Figure 9. Effects of B-box 2 changes on the chimeric rh5RBCC-Cyp protein

(A) The binding of the unmodified rh5RBCC-Cyp (wt) protein and the Cluster I-A (I) and
Cluster II-A (II) derivatives to HIV-1 CA-NC complexes was assessed on 70% sucrose
cushions. TRIM5αrh (rh5) and TRIM5αhu (hu 5) were included as controls. The steady-state
expression level of the unmodified (wt) rhRBCC-Cyp protein was significantly lower than that
of TRIM5αrh, and the Cluster I-A and II-A derivatives of rh5RBCC-Cyp were expressed at
approximately 5-fold higher levels than that of the wt rhRBCC-Cyp protein (data not shown).
In the binding assay, an attempt was made to adjust the amount of input lysate to offset these
different levels of expression. The TRIM5 proteins were detected by Western blotting with an
anti-HA antibody, and the CA-NC protein by an anti-p24 antibody. (B and C) HeLa cells
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stably expressing the indicated proteins were exposed to HIV-1-GFP (B) or N-MLV-GFP
(C). GFP-positive cells were counted. The results of typical experiments are shown.
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